Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The Best 15 Applications for Efficiency and Association - 2Limited Rain Chances in Brazil Boost Coffee Prices
- 3What's going on with Katseye? The Manon Bannerman hiatus drama, explained.
- 4Map shows more than 1,900 measles cases across U.S.
- 5More parents refusing this shot that prevents serious bleeding at birth
- Vote In favor of Your Favored Occasion Arranging Administration
- Was This Driver Simply Having Some good times Or Behaving Like An Ass?
- Vote In favor of Your Favored Web-based Visual depiction Administration
- Disability rights activist and author Alice Wong dies at 51
- The most effective method to Augment Benefits in Gold Speculation: Systems and Tips
- Trial of pro-Palestine activist begins
- NASA unveils close-up pictures of the comet popping by from another star
- Smooth countdown continues for Artemis II moon mission
- More than 800 flights canceled as FAA cuts traffic at 40 major airports. Here's what to know.
